Altre lingue

09/01 Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference
06/01 Aktien New York Schluss: Dow steuert mit Rekord auf 50.000 Punkte zu
06/01 Fortrea Shares Rise After Evercore ISI Upgrade
06/01 Aktien New York: Dow steuert mit Rekord auf 50.000 Punkte zu
06/01 Aktien New York: Schwung für den Dow ebbt etwas ab
06/01 Aktien New York Ausblick: Schwung für den Dow ebbt ab - Nasdaq leicht im Plus
06/01 Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference
15/12 Fortrea Holdings Shares Higher After Barclays Upgrade
11/12 Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04/12 SCTbio and Fortrea forge strategic collaboration to accelerate cell and gene therapy development and delivery
04/12 Sctbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
04/12 Fortrea, SCTbio Collaborate Over Cell, Gene Therapy Development, Delivery
04/12 SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
25/11 Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences
24/11 Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand
24/11 Fortrea Completes Repurchase of $75.7 Million of Senior Notes
24/11 Fortrea completes $75.7 million senior notes tender offer utilizing cash on hand
24/11 Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand
17/11 Fortrea Announces Executive Changes
17/11 Fortrea Appoints Agnieszka Gallagher as General Counsel
15/11 Activist Starboard sells Pfizer stake after pushing for changes
14/11 Starboard Value LP dissolves share stake in Pfizer & Fortrea
07/11 Fortrea Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortrea Holdings, Inc. - FTRE
05/11 Fortrea Holdings Inc. Revises Earnings Guidance for the Full Year 2025
05/11 Fortrea's Q3 Adjusted Earnings Down, Revenue Up; Raises 2025 Revenue Guidance
Non ci sono risultati per questa ricerca